ACLX vs SRPT · rev $107.9M vs rev $1.13B
Arcellx Inc (ACLX) versus Sarepta Therapeutics Inc (SRPT) — a side-by-side from cached financials, not a winner call.
Arcellx Inc (ACLX) is a biotechnology company listed on NASDAQ.
Sarepta Therapeutics Inc (SRPT) is a biotechnology company listed on US.
Latest reported ACLX revenue for 2024-12-31 was $107.9M. Net income was -$107.3M. Revenue was down 2.2% from 2023-12-31 to 2024-12-31. ACLX currently screens at market cap $6.73B.
Latest reported SRPT revenue for 2026-06-30 was $1.13B. Net income was $326.1M. Revenue was up 54.9% from 2026-03-31 to 2026-06-30. SRPT currently screens at market cap $2.34B.
ACLX currently screens at market cap $6.73B. SRPT currently screens at market cap $2.34B.
Not investment advice. Open the ACLX and SRPT stock pages for the full models.
Not investment advice.